Genital Herpes News and Research RSS Feed - Genital Herpes News and Research

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections. [More]
Nanoviricides develops new drug candidates against MERS infection

Nanoviricides develops new drug candidates against MERS infection

... [More]
Johns Hopkins researchers identify protein that regulates the body's immune response to CMV

Johns Hopkins researchers identify protein that regulates the body's immune response to CMV

Infectious disease specialists at the Johns Hopkins Children's Center have identified a protein that regulates the body's immune response to cytomegalovirus (CMV), a common pathogen that causes lifelong infections and can lead to devastating illness in newborns and those with weakened immune systems. [More]
Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013. [More]
Women using DMPA injection more likely to acquire HIV than women using NET-EN

Women using DMPA injection more likely to acquire HIV than women using NET-EN

Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston. [More]
European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever. [More]
Researchers launch clinical trial of investigational vaccine designed to prevent genital herpes disease

Researchers launch clinical trial of investigational vaccine designed to prevent genital herpes disease

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md. [More]
NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide. [More]
Most U.S. adolescents lack antibodies that may help protect against genital herpes, says study

Most U.S. adolescents lack antibodies that may help protect against genital herpes, says study

A new study suggests a growing number of U.S. adolescents lack antibodies that may help protect them later in life against an increasingly important cause of genital herpes. Published in The Journal of Infectious Diseases and available online, the findings show that fewer of today's teens have been exposed in their childhood to herpes simplex virus type 1 (HSV-1), a common cause of cold sores, than U.S. adolescents in previous years. [More]
Discovery paves way for development of new medicines to combat herpes infections

Discovery paves way for development of new medicines to combat herpes infections

Researchers at Lund University in Sweden and Carnegie Mellon University have for the first time managed to measure the internal pressure that enables the herpes virus to infect cells in the human body. The discovery paves the way for the development of new medicines to combat viral infections. The results indicate good chances to stop herpes infections in the future. [More]
Researchers potentially reached milestone in vaccine treatment for genital herpes

Researchers potentially reached milestone in vaccine treatment for genital herpes

Sexually transmitted infection researchers potentially have reached a milestone in vaccine treatment for genital herpes, according to a report to be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver, Colo., on today, Sept. 12. [More]
Pain, itching associated with shingles may be due to virus causing "short circuit" in nerve cells

Pain, itching associated with shingles may be due to virus causing "short circuit" in nerve cells

The pain and itching associated with shingles and herpes may be due to the virus causing a "short circuit" in the nerve cells that reach the skin, Princeton researchers have found. [More]
Apoptosis can reactivate latent herpesviruses in dying cell

Apoptosis can reactivate latent herpesviruses in dying cell

Researchers have found that apoptosis, a natural process of programmed cell death, can reactivate latent herpesviruses in the dying cell. The results of their research, which could have broad clinical significance since many cancer chemotherapies cause apoptosis, was published ahead of print in the Journal of Virology. [More]
NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates. [More]
NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides, Inc. announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever. [More]
European Commission grants orphan drug designation for maribavir for treatment of CMV disease

European Commission grants orphan drug designation for maribavir for treatment of CMV disease

ViroPharma Incorporated today announced that the European Commission has granted orphan drug designation for maribavir for treatment of cytomegaloviral disease in patients with impaired cell mediated immunity. [More]
NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever. [More]
Scientists identify new class of immune cells that suppress genital herpes

Scientists identify new class of immune cells that suppress genital herpes

Fred Hutchinson Cancer Research Center and University of Washington scientists have identified a class of immune cells that reside long-term in the genital skin and mucosa and are believed to be responsible for suppressing recurring outbreaks of genital herpes. [More]
FDA approves Mylan's ANDA for generic version of Zovirax Ointment

FDA approves Mylan's ANDA for generic version of Zovirax Ointment

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Acyclovir Ointment USP, 5%. [More]
Viral protein hijacks cellular machinery and grabs the wheel

Viral protein hijacks cellular machinery and grabs the wheel

Northwestern Medicine scientists have identified a component of the herpesvirus that "hijacks" machinery inside human cells, allowing the virus to rapidly and successfully invade the nervous system upon initial exposure. [More]